Bae Yu-Kyung, Na Hyo-Seok, Hwang Jung-Won, Lim Young-Jin, Do Sang-Hwan
Department of Anesthesiology & Pain Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.
Department of Anesthesiology & Pain Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
J Clin Med. 2024 Sep 6;13(17):5299. doi: 10.3390/jcm13175299.
: Neuromuscular blocking agents (NMBAs) are not usually necessary during the induction of general anesthesia in patients using supraglottic airway (SGA) devices. In this study, we assessed the incidences of rocuronium use in adult patients undergoing general anesthesia using SGA devices. : From September 2022 to August 2023, the medical records of adult patients (≥19 years) who underwent orthopedic surgery using SGA devices were retrospectively investigated. The incidences of rocuronium use during anesthetic induction were analyzed according to the anesthetic induction drug. The association of rocuronium use during anesthesia was analyzed in terms of demographic (age, sex, height, and weight), surgical (surgical time), and anesthetic factors (premedication, anesthetic agent, anesthetic time). : In total, 321 patients were enrolled. The incidence rate of rocuronium use during anesthetic induction was 28.3%. In the subgroup analysis, patients receiving total intravenous anesthesia (TIVA) with propofol (PPF) and remifentanil showed a markedly lower incidence (14.4%) than the other anesthetic groups. Premedication or short anesthetic duration was associated with lower incidences of rocuronium use. Demographic and other anesthetic factors did not seem to affect the incidences of rocuronium use during anesthesia. : The incidence of rocuronium use during anesthetic induction with SGA devices was significantly lower with the PPF-TIVA compared to that using remimazolam-TIVA or inhalational anesthesia. Premedication with midazolam and shorter operation times were associated with a significantly lower incidence of rocuronium use.
在使用声门上气道(SGA)装置的患者全身麻醉诱导过程中,通常不需要使用神经肌肉阻滞剂(NMBAs)。在本研究中,我们评估了使用SGA装置进行全身麻醉的成年患者中罗库溴铵的使用发生率。
从2022年9月至2023年8月,对使用SGA装置接受骨科手术的成年患者(≥19岁)的病历进行了回顾性调查。根据麻醉诱导药物分析麻醉诱导期间罗库溴铵的使用发生率。从人口统计学(年龄、性别、身高和体重)、手术(手术时间)和麻醉因素(术前用药、麻醉剂、麻醉时间)方面分析麻醉期间罗库溴铵使用的相关性。
总共纳入了321例患者。麻醉诱导期间罗库溴铵的使用发生率为28.3%。在亚组分析中,接受丙泊酚(PPF)和瑞芬太尼全静脉麻醉(TIVA)的患者发生率(14.4%)明显低于其他麻醉组。术前用药或麻醉时间短与罗库溴铵使用发生率较低相关。人口统计学和其他麻醉因素似乎不影响麻醉期间罗库溴铵的使用发生率。
与使用瑞马唑仑-TIVA或吸入麻醉相比,PPF-TIVA在使用SGA装置进行麻醉诱导期间罗库溴铵的使用发生率显著更低。咪达唑仑术前用药和较短的手术时间与罗库溴铵使用发生率显著降低相关。